Processa Pharmaceuticals, Inc. PCSA

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
19/100
Weak

About Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 … Full PCSA analysis →

Competitive advantage assessment

Key risks

  • ROIC Below WACC or Peers ROIC at 10.9th percentile suggests inefficient capital deployment.
  • Elevated Debt Risk Debt serviceability is weak (score 0.25), raising refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Insufficient Data
—

Where PCSA ranks in Biotechnology

Processa Pharmaceuticals, Inc. ranks #609 of 713 scored companies in Biotechnology by moat score — the top 85%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

Moat scores for companies ranked near PCSA in Biotechnology
# Company Moat score Rating
605 Hepion Pharmaceuticals, Inc. HEPA 20/100 Weak
606 Connect Biopharma Holdings Limi CNTB 20/100 Weak
607 eXoZymes, Inc. EXOZ 20/100 Weak
608 PolyPid Ltd. PYPD 20/100 Weak
609 Processa Pharmaceuticals, Inc. PCSA 19/100 Weak
610 Senti Biosciences, Inc. SNTI 19/100 Weak
611 Eterna Therapeutics Inc. ERNA 19/100 Weak
612 TransCode Therapeutics, Inc. RNAZ 18/100 Weak
613 IO Biotech, Inc. IOBT 18/100 Weak

See every Biotech / Pre-Revenue company ranked by moat score →

How PCSA scores on the Corporate Default defenses

Pricing Power

Not measurable · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Not measurable · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Not measurable · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 14 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 27 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Not measurable · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding PCSA's moat

What is Processa Pharmaceuticals, Inc.'s moat score?

Processa Pharmaceuticals, Inc. (PCSA) scores 19 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as weak. It ranks #609 of 713 scored companies in Biotechnology, the top 85%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Resilience (27/100) and its weakest is Capital Efficiency (14/100).

How does Processa Pharmaceuticals, Inc. compare with other Biotechnology companies?

Processa Pharmaceuticals, Inc. ranks #609 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are PolyPid Ltd. (PYPD) at 20 just above it and Senti Biosciences, Inc. (SNTI) at 19 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Processa Pharmaceuticals, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Processa Pharmaceuticals, Inc.?

The Corporate Default template measures 6 defenses, and PCSA scores: Pricing Power (not measurable), Cost Advantage (not measurable), Customer Stickiness (not measurable), Capital Efficiency (14), Resilience (27), Scale & Market Position (not measurable). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000